Zobrazeno 1 - 10
of 921
pro vyhledávání: '"Lutetium-177"'
Autor:
Rajan Singh, Anand K. Thotakura, Suresh Alati, Alla Lisok, Zirui Jiang, Vanessa F. Merino, Il Minn, Santosh Yadav, Mark C. Markowski, Yasser Ged, Christian P. Pavlovich, Nirmish Singla, Lilja B. Solnes, Michael A. Gorin, Martin G. Pomper, Steven P. Rowe, Sangeeta Ray Banerjee
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionRenal cell carcinoma (RCC) represents cancer originating from the renal epithelium and accounts for > 90% of cancers in the kidney. Prostate-specific membrane antigen (PSMA) is overexpressed in tumor-associated neovascular endothelial cel
Externí odkaz:
https://doaj.org/article/0b43bcfa255e43f883bee194298d2a44
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 12, Iss 4, Pp 27-39 (2023)
Introduction. The use of radiopharmaceuticals for targeted radionuclide therapy (TRT), the efficacy of which was established during clinical trials, is safe and effective for various pathological conditions, including cancer. The main feature of ther
Externí odkaz:
https://doaj.org/article/92b1f8adb25e438b91354b1363517f28
Autor:
Matthias Balzer, Fleur Spiecker, Stephanie Bluemel, Holger Amthauer, Winfried Brenner, Sarah Spreckelmeyer
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 8, Iss 1, Pp 1-8 (2023)
Abstract Background 177Lu-radiopharmaceuticals can contain the metastable impurity [177mLu]lutetium with a physical half-life of 160.4 days, in varying concentrations depending on the route of production of the radionuclidic precursor [177Lu]lutetium
Externí odkaz:
https://doaj.org/article/a0e4d808f216416f8c873bad43081709
Autor:
Rien Ritawidya, Hendris Wongso, Nurmaya Effendi, Anung Pujiyanto, Wening Lestari, Herlan Setiawan, Titis Sekar Humani
Publikováno v:
Advanced Pharmaceutical Bulletin, Vol 13, Iss 4, Pp 701-711 (2023)
Prostate-specific membrane antigen (PSMA) represents a promising target for PSMA-overexpressing diseases, especially prostate cancer-a common type of cancer among men worldwide. In response to the challenges in tackling prostate cancers, several prom
Externí odkaz:
https://doaj.org/article/e7563736b1504f889fdfab272e566029
Autor:
Wolfgang Roll, Michael Müther, Guido Böning, Astrid Delker, Nils Warneke, Franz-Josef Gildehaus, Michael Schäfers, Walter Stummer, Reinhard Zeidler, Hans-Jürgen Reulen, Lars Stegger
Publikováno v:
EJNMMI Research, Vol 13, Iss 1, Pp 1-8 (2023)
Abstract Background Following resection and standard adjuvant radio- and chemotherapy, approved maintenance therapies for glioblastoma are lacking. Intracavitary radioimmunotherapy (iRIT) with 177Lu-labeled 6A10-Fab fragments targeting tumor-associat
Externí odkaz:
https://doaj.org/article/4b7795c149c041df88ca457cecc3e060
Autor:
Jules Zhang-Yin
Publikováno v:
Biomedicines, Vol 12, Iss 7, p 1512 (2024)
Lutetium-177 (Lu-177)-labelled radioligand therapies (RLT) targeting prostate-specific membrane antigen (PSMA) present a promising treatment for patients with progressive metastasized castration-resistant prostate cancer (mCRPC). Personalized dosimet
Externí odkaz:
https://doaj.org/article/17292e342bb449eab2a5c8cf750a1f33
Autor:
Tilman Läppchen, Adrianna Bilinska, Eirinaios Pilatis, Elena Menéndez, Surachet Imlimthan, Euy Sung Moon, Ali Afshar-Oromieh, Frank Rösch, Axel Rominger, Eleni Gourni
Publikováno v:
Molecules, Vol 29, Iss 13, p 3093 (2024)
Background: FAP radiopharmaceuticals show promise for cancer diagnosis; however, their limited tumor residency hinders treatment. This study compared two FAPi derivatives, DOTA.SA.FAPi and DOTAGA.(SA.FAPi)2, labeled with gallium-68 and lutetium-177,
Externí odkaz:
https://doaj.org/article/285d4217cb994469b1b11d23d67b90fa
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 8, Iss 1, Pp 1-16 (2023)
Abstract Background Pancreatic ductal adenocarcinoma (PDAC) continues to be a malignancy with an unmet clinical demand. Development of radioimmunoconjugates which target cancer-specific receptors provides an opportunity for radioimmunotherapy of both
Externí odkaz:
https://doaj.org/article/0e6a9c6427e044eca543f2af2fff269f
Autor:
Maryana Handula, Savanne Beekman, Mark Konijnenberg, Debra Stuurman, Corrina de Ridder, Frank Bruchertseifer, Alfred Morgenstern, Antonia Denkova, Erik de Blois, Yann Seimbille
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 8, Iss 1, Pp 1-16 (2023)
Abstract Background The [177Lu]Lu-DOTA-TATE mediated peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NETs) is sometimes leading to treatment resistance and disease recurrence. An interesting alternative could be the somatostati
Externí odkaz:
https://doaj.org/article/b4c3e0284752465fa8ed5d7be031a77d
Autor:
Silvano Gnesin, Nicolas Chouin, Michel Cherel, Steven Mark Dunn, Niklaus Schaefer, Alain Faivre-Chauvet, John O. Prior, Judith Anna Delage
Publikováno v:
EJNMMI Research, Vol 13, Iss 1, Pp 1-11 (2023)
Abstract The development of diagnostic and therapeutic radiopharmaceuticals is an hot topic in nuclear medicine. Several radiolabeled antibodies are under development necessitating both biokinetic and dosimetry extrapolations for effective human tran
Externí odkaz:
https://doaj.org/article/675c9d24f452478b9c0e94b40b313ada